Abstract:
:Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.
journal_name
Cancer Treat Revjournal_title
Cancer treatment reviewsauthors
Barata P,Sood AK,Hong DSdoi
10.1016/j.ctrv.2016.08.004subject
Has Abstractpub_date
2016-11-01 00:00:00pages
35-47eissn
0305-7372issn
1532-1967pii
S0305-7372(16)30074-3journal_volume
50pub_type
杂志文章,评审abstract::Hyperprogressive disease (HPD) is a concerning paradoxical acceleration of cancer growth induced by immune drugs. The lack of standard radiological criteria makes its study challenging. We reviewed the literature and compared the main criteria for HPD proposed by Ferté, Le Tourneau, Garralda and Caramella to address t...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2020.102116
更新日期:2020-12-01 00:00:00
abstract::Metastatic colorectal cancer (CRC) is most frequently seen in the liver. Resection of metastases remains the treatment of choice; however, the majority of patients are ineligible for surgery due to unfavorable location, size, or number of metastases; insufficient liver reserve; or extrahepatic disease. The activity of...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.01.004
更新日期:2008-06-01 00:00:00
abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(93)90004-b
更新日期:1993-04-01 00:00:00
abstract::We have previously shown that the stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK monomer) leads to a good tolerance of otherwise lethal multiple ara-C doses and an increased survival of ara-C + peptide treated mice. This effect was due to the prevention of drug-induced CFU-S proliferation, thus keeping stem...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/0305-7372(90)90068-q
更新日期:1990-09-01 00:00:00
abstract::Hepatocellular carcinoma (HCC) is one of the most frequent and deadliest cancers worldwide. Liver transplantation, surgical resection or local ablation offer the best survival advantages but most patients either present when the tumor is in an advanced stage or the degree of underlying liver disease precludes these op...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2011.05.002
更新日期:2012-02-01 00:00:00
abstract::Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.06.009
更新日期:2014-09-01 00:00:00
abstract::Patient-controlled analgesia (PCA) was administered in the domiciliary environment in 143 pre-terminally and terminally ill tumour patients suffering either from excruciating chronic pain or severe chronic/acute complex pain that could not be relieved adequately by oral analgesia. Morphine solutions were infused subcu...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/s0305-7372(96)90076-6
更新日期:1996-01-01 00:00:00
abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1053/ctrv.1999.0152
更新日期:2000-04-01 00:00:00
abstract::Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(02)00107-x
更新日期:2003-04-01 00:00:00
abstract::In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the clinician's therapeutic armamentarium. On the other hand, numerous classic cytotoxic agents are currently considered as potential an...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2011.09.002
更新日期:2012-08-01 00:00:00
abstract:PURPOSE:To conduct a systematic review and meta-analysis of all phase III randomized controlled trials comparing efficacy of early versus late first-line or initial treatments for cancer. METHODS:A comprehensive literature search of MEDLINE and Cochrane library databases was performed (1966-2008). Data was extracted a...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.ctrv.2010.04.001
更新日期:2010-12-01 00:00:00
abstract::Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers and remains a challenge in oncology. In 1997, gemcitabine became the standard of care in metastatic setting. In the last decades, despite a number of clinical trials assessing novel cytotoxic agents and cell signaling inhibitors, overall sur...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.10.002
更新日期:2009-04-01 00:00:00
abstract::The role of adjuvant chemotherapy in patients with stage III colon cancer is now well established and 5-FU/LV should be the reference regimen to which new drugs are tested against in the adjuvant setting. In stage II colon cancer, because the risk of recurrence is lower, any absolute benefit of chemotherapy is likely ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(02)00047-6
更新日期:2002-10-01 00:00:00
abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.03.001
更新日期:2013-02-01 00:00:00
abstract::Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was est...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2005.05.007
更新日期:2005-10-01 00:00:00
abstract::Non-small cell lung cancer (NSCLC) is the biggest cancer killer in the United States and worldwide. In 2011, there are estimated to be 221,130 new cases of lung cancer in the United States. Over a million people will die of lung cancer worldwide this year alone. When possible, surgery to remove the tumor is the best t...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2011.11.008
更新日期:2012-10-01 00:00:00
abstract::We have established that drug resistance can be expressed following in vitro exposure of tumour cells not only to antitumor drugs but also to fractionated X-irradiation. These data therefore suggest a biological basis for the clinical problem of drug resistance that can occur in patients with previously irradiated tum...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(90)90012-5
更新日期:1990-12-01 00:00:00
abstract::Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rational...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.01.004
更新日期:2010-08-01 00:00:00
abstract::Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2006.01.004
更新日期:2006-05-01 00:00:00
abstract::Prostate cancer is a significant cause of morbidity and mortality in the United States and Europe. The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(03)00096-3
更新日期:2003-06-01 00:00:00
abstract::Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(97)90022-0
更新日期:1997-03-01 00:00:00
abstract::The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in ce...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(84)90024-0
更新日期:1984-12-01 00:00:00
abstract::The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2018.05.005
更新日期:2018-06-01 00:00:00
abstract::Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2019.04.004
更新日期:2019-06-01 00:00:00
abstract::Cancer cells exhibit deregulation in multiple cellular signaling pathways. Therefore, treatments using specific agents that target only one pathway usually fail in cancer therapy. The combination treatments using chemotherapeutic agents with distinct molecular mechanisms are considered more promising for higher effica...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2009.07.001
更新日期:2009-11-01 00:00:00
abstract::Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumour types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC). This agent has a generally favourable safety profile, and may be suitable for use in special populations s...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2005.12.008
更新日期:2006-04-01 00:00:00
abstract::Tumour budding reflects a detachment of tumour cells at the invasive front of carcinomas and is presumed to be an early step in the metastatic process. Tumour budding has received some attention in colorectal cancer as it has been proposed as an additional prognostic factor in colorectal cancer that may stratify patie...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.12.007
更新日期:2015-02-01 00:00:00
abstract::Currently, platinum-based combination chemotherapy is the standard first-line chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based chemotherapy has been recommended for up to six cycles even for responders, and second-line chemotherapy has been considered when disease progression is confir...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.12.007
更新日期:2011-11-01 00:00:00
abstract:PURPOSE:To summarize and define the methodological quality of primary research findings obtained in exercise interventions, aimed at improving physical function or psychological well-being in patients treated for haematological malignancies. METHODS:Relevant trials were identified through a computerized Mesh-search in...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.09.008
更新日期:2009-04-01 00:00:00
abstract::Pancreatic cancer represents the fourth leading cause of cancer death in men and the fifth in women. Prognosis remains dismal, mainly because the diagnosis is made late in the clinical course of the disease. The need to improve the diagnosis, detection, and treatment of pancreatic cancer is great. It is in this type o...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1053/ctrv.1999.0144
更新日期:2000-02-01 00:00:00